

# Morning Note



### CORA GOLD (CORA): CORP

#### Definitive Feasibility Study and Optimised Economics released

Cora Gold offers exposure to a significant gold exploration and development business with a lead project at Sanankoro in south western Mali. The company has now released the results of the Definitive Feasibility Study (DFS) for Sanankoro and at the same time has also released an optimised update with improved project economics. The net result is an unrisked NPV for the project of US\$95.1m – this is a significant multiple of the company's current market capitalisation.

### ENGAGE XR HOLDINGS (EXR): CORP

#### Reseller agreement with Lenovo to scale the ENGAGE platform

Following Lenovo being announced as a launch partner of ENGAGE Link on 28 September, ENGAGE XR and Lenovo have signed a commercial reseller agreement. The agreement enables Lenovo to resell and distribute end-user licences for the proprietary ENGAGE platform, and ENGAGE XR and Lenovo will also work together on the sales and marketing of the recently launched ENGAGE Link. Through reselling the ENGAGE platform, Lenovo will be able to accelerate the growth of its ThinkReality VRX headset, which launches in early 2023, while the agreement marks a major endorsement of the ENGAGE platform by a company with over \$70bn of revenue, a global salesforce, and many existing enterprise customers that would be new customers for ENGAGE. Following the launch of ENGAGE Link on 7 November, we look forward to further updates on its momentum, and further detail on the group's performance at the FY22 trading update in January. We make no changes to our forecasts at this point, and as ENGAGE XR is strengthening and expanding across multiple fronts, we value the platform at 80p using a scenario-based approach to capture the wide range of potential outcomes for extended reality solutions. At 12p, it is trading on 5x 12-month forward EV/Sales with +99% NTM Sales growth.

### GENEDRIVE (GDR): CORP

#### FY results: good technical progress

genedrive reported FY results to June 2022. The company has had a positive year in terms of technical and regulatory progress, but revenue generation will take longer to achieve and the company notes that generating commercial traction with multiple innovative products will require further financing.

#### 21 November 2022

# Corp

Net debt/(cash)

Enterprise value

Target price

Other EV adjustments

Ticker	CORA:AIM
Mining	
Shares in issue (m)	289.6
Next results	FY Mar
Price	4.3p
Target price	30.0p
Upside	606%
Market cap	£12.3m

Zinter prioce variate		20.0
What's changed?	From	То
Adjusted EPS	-	-0.7


-£4.0m

£0.0m

f8 3m

30.0

#### Share price performance



%	1M	3M	12M
Actual	-9.6	-12.4	-63.4

#### Company description

Cora Gold is a gold exploration and development company with assets in Mali.

#### **Martin Potts**

Research Analyst mpotts@finncap.com 020 3772 4683

 Sales desk
 020 7220 0522

 Trading desk
 020 7220 0533

\* denotes corporate client of finnCap

# CORA GOLD\*

# Definitive Feasibility Study and Optimised Economics released

Cora Gold offers exposure to a significant gold exploration and development business with a lead project at Sanankoro in south western Mali. The company has now released the results of the Definitive Feasibility Study (DFS) for Sanankoro and at the same time has also released an optimised update with improved project economics. The net result is an unrisked NPV for the project of US\$95.1m – this is a significant multiple of the company's current market capitalisation.

- The Sanankoro optimised project economics are based on a gold price of US\$1,750/oz (currently trading at US\$1,746/oz) and an initial Mining Reserve of 422,000 ounces of gold contained within 10.1 million tonnes of ore grading 1.30 g/t. The ore is mostly oxidised material and so should be straightforward to mine and process with gold recoveries expected to be 90.1% using a conventional 1.5 mtpa Carbon in Leach process plant. This gives a 6.8 year mine life based on the currently defined Reserve. Cash costs are estimated at US\$771/oz with all-in sustaining costs of US\$997/oz at current gold prices.
- In economic terms the project has an IRR of 52.3% and a rapid 1.2 year payback. This is primarily because of the oxidised nature of the ore. The post-tax NPV using an 8% discount rate is calculated to be US\$95.1m.
- Up-front capital is estimated to be US\$90m, reduced from initial estimates by using a second-hand grinding mill and by making other detailed design changes based on discussions with contracting and mine construction companies with extensive experience in West Africa. Interestingly, the design includes a hybrid power option incorporating solar power. The company expects to make use of contractors for the actual mining operation. This reduces the up-front capex but has a negative impact on operating costs. This is standard practice for a mining startup.
- There is substantial upside from the present optimised DFS, based on a further 121,000 ounces of gold withing currently defined Resources. This would add a further 2.5 years to the mine life. This Resource needs infill drilling before it can be converted to Reserve. Beyond that, there is potential for as much as 1.3 million ounces as an Exploration Target though this needs further work to properly define it.

Key estimates		2020A	2021A	2022E	2023E	2024E
Year end:		Dec	Dec	Dec	Dec	Dec
Revenue	\$m	0.0	0.0	0.0	0.0	0.0
Adj EBITDA	\$m	-0.7	-1.3	-1.9	-2.1	-2.3
Adj EBIT	\$m	-0.7	-1.3	-1.9	-2.1	-2.3
Adj PBT	\$m	-0.7	-1.3	-1.9	-2.1	-2.3
Adj EPS	С	-0.4	-0.6	-0.7	-0.7	-0.8
DPS	С	0.0	0.0	0.0	0.0	0.0

Key valuation metric	S					
EV/EBIT (adj)	Х	-13.6	-7.6	-5.2	-4.7	-4.3
P/E (adj)	Х	-12.2	-9.1	-7.7	-7.0	-6.4
Dividend yield	%	0.0%	0.0%	0.0%	0.0%	0.0%
Free cash yield	%	-20.4%	-62.8%	-47.0%	-48.4%	-49.7%
Pre-tax ROCE	%	-4.0%	-4.9%	-54.7%	-152.6%	-213.8%

#### 21 November 2022

# Corp

Ticker	EXR:AIM
Software & Computer Services	
Shares in issue (m)	290.1
Next results	FY Mar
Price	11.8p
Target price	80.0p
Upside	581%
Market cap	£34.1m
Net debt/(cash)	-£4.3m
Other EV adjustments	£0.0m
Enterprise value	£29.8m

What's changed?	From	То
Adjusted EPS	-1.4	n/c
Target price	80.0	n/c

#### Share price performance



%	1M	3M	12M
Actual	-16.1	20.5	-30.9

#### Company description

ENGAGE XR operates a cloud-based, extended reality software platform

#### Michael Hill

Director of Research mhill@finncap.com 020 7220 0554

Sales desk 020 7220 0522

Trading desk 020 7220 0533

\* denotes corporate client of finnCap

# ► ENGAGE XR HOLDINGS\*

# Reseller agreement with Lenovo to scale the ENGAGE platform

Following Lenovo being announced as a launch partner of ENGAGE Link on 28 September, ENGAGE XR and Lenovo have signed a commercial reseller agreement. The agreement enables Lenovo to resell and distribute end-user licences for the proprietary ENGAGE platform, and ENGAGE XR and Lenovo will also work together on the sales and marketing of the recently launched ENGAGE Link. Through reselling the ENGAGE platform, Lenovo will be able to accelerate the growth of its ThinkReality VRX headset, which launches in early 2023, while the agreement marks a major endorsement of the ENGAGE platform by a company with over \$70bn of revenue, a global salesforce, and many existing enterprise customers that would be new customers for ENGAGE. Following the launch of ENGAGE Link on 7 November, we look forward to further updates on its momentum, and further detail on the group's performance at the FY22 trading update in January. We make no changes to our forecasts at this point, and as ENGAGE XR is strengthening and expanding across multiple fronts, we value the platform at 80p using a scenario-based approach to capture the wide range of potential outcomes for extended reality solutions. At 12p, it is trading on 5x 12-month forward EV/Sales with +99% NTM Sales growth.

- **ENGAGE Link** The <u>ENGAGE Link</u> platform is an evolution of the group's immersive communications platform, ENGAGE, and is designed for customers to create their own virtual worlds to provide services directly to their own clients, and engage with their employees, suppliers, and other stakeholders. It is split into four plazas, with the Central Plaza serving as the starting point for new visitors, from which they can walk through portals to locations within the ENGAGE metaverse or other platforms. The Enterprise Plaza enables organisations to create their own virtual world to deliver meetings, product launches, demonstrations, training days, and events. The Education Plaza hosts educational institutions, and the 10 Meta-funded 'Metaversities' are already using ENGAGE Link for thousands of students. The Creative Plaza serves as a location for brands, artists, and content studios, where it will showcase some of the most creative ideas in the metaverse, including a virtual concert with FatBoy Slim in early 2023.
- Investment case As we explain in more depth in our March <u>initiation</u>, ENGAGE XR is focused on achieving its potential within extended reality through leveraging its proprietary cloud-based platform, a focus on data security, and an excellent reputation for reliability and stability. The initial development of its immersive platform in 2015 has enabled an early-mover advantage in XR, and it already benefits from a blue-chip customer base that includes 3M, HTC, Meta (Facebook), Unilever, KPMG, the US Department of State, Audi, BMW, Vodafone, and Stanford University. A market share of only 1% of the current global team collaboration software market would correspond to over \$100m of revenue, with further upside possible from complementary markets such as events and training, and transformational potential as its platform evolves into the metaverse through ENGAGE Link.

Key estimates		2019A	2020A	2021A	2022E	2023E
Year end:		Dec	Dec	Dec	Dec	Dec
Revenue	€m	1.0	1.4	2.4	4.9	9.7
Adj EBITDA	€m	-1.4	-2.0	-2.4	-3.8	-1.0
Adj EBIT	€m	-1.9	-2.7	-3.0	-4.2	-1.2
Adj PBT	€m	-1.9	-2.7	-3.0	-4.2	-1.2
Adj EPS	С	-1.0	-1.1	-1.0	-1.4	-0.4
DPS	С	0.0	0.0	0.0	0.0	0.0

Key valuation metric	S					
EV/EBIT (adj)	Х	-17.8	-12.6	-11.3	-8.1	-28.3
P/E (adj)	X	-13.5	-12.0	-13.9	-9.3	-32.6
Dividend yield	%	0.0%	0.0%	0.0%	0.0%	0.0%
Free cash yield	%	-5.6%	-5.7%	-7.0%	-10.8%	-3.8%
Pre-tax ROCE	%	-66.8%	-87.5%	-35.5%	-97.8%	-38.4%

#### 21 November 2022

# Corp

# Ticker GDR:AIM Pharmaceuticals & Biotechnology

Shares in issue (m) 91.8


Next results FY Nov

Price12.8pTarget priceUnder reviewUpsiden/a

Market cap£11.7mNet debt/(cash)-£3.0mOther EV adjustments£0.0mEnterprise value£8.7m

What's changed?FromToAdjusted EPSU/Rn/cTarget priceU/Rn/c

#### Share price performance



%	1M	3M	12M
Actual	4.1	-30.1	-30.1

#### Company description

Molecular diagnostic company with point-of-care PCR technology

#### **Mark Brewer**

Director of Research mbrewer@finncap.com 020 7220 0556

#### Dr Stephen McGarry

Director of Research smcgarry@finncap.com 020 7220 0550

 Sales desk
 020 7220 0522

 Trading desk
 020 7220 0533

\* denotes corporate client of finnCap

# **▶**GENEDRIVE\*

# FY results: good technical progress

genedrive reported FY results to June 2022. The company has had a positive year in terms of technical and regulatory progress, but revenue generation will take longer to achieve and the company notes that generating commercial traction with multiple innovative products will require further financing.

- **Results.** The group reported revenue of £0.049m, R&D spend of £3.9m, an operating loss of £5.6m, a net loss of £4.7m and a loss per share of 5.5p. Net cash at end-June 2022 was £4.6m. Since year-end, the cash burn has averaged £0.4m per month and unaudited net cash at the end of October was £3.0m. If cash burn continues at that rate, in the absence of significant revenue generation, the Group's cash runway extends until around the end of June 2023. Any notable revenue generation would extend that further. genedrive has noted that it will seek the additional funding that will be needed to generate traction in terms of revenue generation.
- Technical and regulatory progress. genedrive's technical and regulatory achievements in the last year include: 1) first NHS Deployments and sales of the Genedrive System for Antibiotic Induced Hearing Loss (AIHL) at Manchester Hospitals; 2) launched 2nd generation Genedrive System to support strategy focus of assay development to emergency care settings; 3) NICE accelerated evaluation of the Genedrive MT-RNR1 ID test; 4) NICE includes Genedrive CYP2C19 ID Kit in Diagnostics Assessment Programme; 5) Point-of-Care Genedrive COV19-ID Kit received Coronavirus Test Device Approval ('CTDA'); 6) new product development programme initiated for use of Genedrive Point-of-Care device for ischemic stroke treatment in emergency care settings; and 7) filed US FDA Pre-submission for the Genedrive MT-RNR1 ID product range. The MT-RNR1 (AIHL) test evaluation by NICE could reach the consultation stage by February 2023; a positive outcome would likely help propel sales of the test in the UK and arguably bode well for the same outcome from the US FDA submission.
- Forecasts and valuation. Given the group's note that it will look to seek additional funding before it is likely to generate significant commercial traction, its for now limited cash runway and until we have visibility over orders for both AIHL and COVID-19 POC tests, which are undergoing evaluations with regulators and distributors, we are leaving our forecasts and target price under review.

key estimates		2019A	2020A	2021A	ZUZZA	2023E
Year end:		Jun	Jun	Jun	Jun	Jun
Revenue	£m	2.4	1.1	0.7	0.0	U/R
Adj EBITDA	£m	-4.3	-5.6	-5.2	-5.3	U/R
Adj EBIT	£m	-4.4	-5.6	-5.5	-5.6	U/R
Adj PBT	£m	-4.4	-5.6	-5.5	-5.6	U/R
Adj EPS	р	-11.9	-11.7	-6.9	-5.5	U/R
DPS	р	0.0	0.0	0.0	0.0	U/R

Key valuation metrics									
EV/EBIT (adj)	Х	-2.0	-1.6	-1.6	-1.6	U/R			
P/E (adj)	X	-1.1	-1.1	-1.8	-2.3	U/R			
Dividend yield	%	0.0%	0.0%	0.0%	0.0%	U/R			
Free cash yield	%	-31.6%	-32.6%	-45.2%	-40.0%	U/R			
Pre-tax ROCE	%	-72.8%	-67.9%	-152.5%	-99.2%	U/R			

Morning Note 21 November 2022

Research					
Mark Brewer David Buxton Kimberley Carstens Michael Clifton Lorne Daniel Andrew Darley Guy Hewett	020 7220 0556 020 7220 0542 020 7220 0548 020 3772 4682 020 7220 0545 020 7220 0547 020 7220 0549	mbrewer@finncap.com dbuxton@finncap.com kcarstens@finncap.com mclifton@finncap.com Idaniel@finncap.com adarley@finncap.com ghewett@finncap.com	Michael Hill Stephen McGarry Mark Paddon Nigel Parson Martin Potts Jonathan Wright	020 7220 0554 020 7220 0550 020 7220 0541 020 7220 0544 020 3772 4683 020 7220 0543	mhill@finncap.com smcgarry@finncap.com mpaddon@finncap.com nparson@finncap.com mpotts@finncap.com jwright@finncap.com
Equity Capital Markets Andrew Burdis Barney Hayward Alice Lane Tim Redfern	020 7220 0524 020 7220 0518 020 7220 0523 020 7220 0515	aburdis@finncap.com bhayward@finncap.com alane@finncap.com tredfern@finncap.com	Sunila de Silva Charlotte Sutcliffe Harriet Ward	020 7220 0521 020 7220 0513 020 7220 0512	sdesilva@finncap.com csutcliffe@finncap.com hward@finncap.com
Sales James Fletcher Louise Talbot Jonathon Webb	020 3772 4657 020 3772 4651 020 7220 0511	jfletcher@finncap.com ltalbot@finncap.com jwebb@finncap.com	Ruth Watts Rhys Williams	020 7220 0520 020 7220 0522	rwatts@finncap.com rwilliams@finncap.com
Investor Relations Brittany Henderson Lucy Nicholls	020 7220 0592 020 7220 0528	bhenderson@finncap.com Inicholls@finncap.com	Brittany Stevens Helen Worrall	020 3772 4653 020 3772 4652	bstevens@finncap.com hworrall@finncap.com
Sales Trading Kai Buckle Charlie Evans	020 7220 0529 020 7220 0531	kbuckle@finncap.com cevans@finncap.com	Daniel Smith	020 7220 0533	dsmith@finncap.com
Market Makers Steve Asfour Jamie Dunleavy	020 7220 0539 020 7220 0534	sasfour@finncap.com jdunleavy@finncap.com	Oliver Ratcliff James Revell	020 7220 0530 020 7220 0532	oratcliff@finncap.com jrevell@finncap.com
Investment Companies Johnny Hewitson Monica Tepes	020 7720 0558 020 3772 4698	jhewitson@finncap.com mtepes@finncap.com	Pauline Tribe Mark Whitfeld	020 7220 0517 020 3772 4697	ptribe@finncap.com mwhitfeld@finncap.com

<sup>\*</sup> finnCap is contractually engaged and paid by the issuer to produce this material on an ongoing basis and it is made available at the same time to any person wishing to receive it.

A marketing communication under FCA Rules, this document has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This research cannot be classified as objective under finnCap Ltd research policy. Visit www.finncap.com

The recommendation system used for this research is as follows. We expect the indicated target price to be achieved within 12 months of the date of this publication. A 'Hold' indicates expected share price performance of +/-10%, a 'Buy' indicates an expected increase in share price of more than 10% and a 'Sell' indicates an expected decrease in share price of more than 10%.

Approved and issued by finnCap Ltd for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to Professional customers. Retail customers who receive this document should ignore it. finnCap Ltd uses reasonable efforts to obtain information from sources which it believes to be reliable, but it makes no representation that the information or opinions contained in this  $document\ are\ accurate,\ reliable\ or\ complete.\ Such\ information\ and\ opinions\ are\ provided\ for\ the\ information$ of finnCap Ltd's clients only and are subject to change without notice. finnCap Ltd's salespeople, traders and other representatives may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to or inconsistent with the opinions expressed herein. This document should not be copied or otherwise reproduced. finnCap Ltd and any company or individual connected with it may have a position or holding in any investment mentioned in this document or a related investment. finnCap Ltd may have been a manager of a public offering of securities of this company within the past 12 months, or have received compensation for investment banking services from this company within the past 12 months, or expect to receive or may intend to seek compensation for investment banking services from this company within the next three months. Nothing in this document should be construed as an offer or solicitation to acquire or dispose of any investment or to engage in any other transaction. finnCap Ltd is authorised and regulated by the Financial Conduct Authority, London E20 1JN, and is a member of the London Stock Exchange.

Morning Note 21 November 2022

#### Additional Information for U.S. Persons

To the extent that any finnCap research is furnished to U.S. recipients, it furnished in reliance on Rule 15a-6 ("Rule 15a-6") under the U.S. Securities Exchange Act of 1934, as amended. The information contained in this research is intended solely for certain "major U.S. institutional investors" (as such term is defined in Rule 15a-6, an "MII") and may not be used or relied upon by any other person for any purpose. Each U.S. recipient of this research represents and agrees, by virtue of its acceptance thereof, that it is a MII and that it understands the risks involved in executing transactions in such securities. Any U.S. recipient of this research that wishes to discuss or receive additional information regarding any security mentioned herein, or engage in any transaction to purchase or sell or solicit or offer the purchase or sale of such securities, should contact a registered representative of Beech Hill Securities, Inc., a U.S. broker-dealer registered with the Securities and Exchange Commission and a Member of FINRA, located at 880 Third Avenue, 16th Floor, New York, NY 10022. Any transaction by a U.S. person (other than a registered U.S. broker-dealer or bank acting in a broker-dealer capacity) must be effected with or through Beech Hill Securities, Inc., which may be contacted via telephone at +1 (212) 350-7200.

This research was prepared by the analyst named on the cover of this research, who is a non-U.S. research analyst of finnCap and, as such, may not be subject to all requirements applicable to U.S.-based analysts.

All of the views expressed in this research accurately reflect the research analyst's personal view about all of the subject securities or research subjects and no part of such analyst's compensation was, is, or will be related to the specific recommendation or view contained in this research.

To the extent this research relates to non-U.S. securities, note that investing in non-U.S. securities may entail particular risks. Such securities may not be registered under the U.S. Securities Act of 1933, as amended, and the issuer of such securities may not be subject to U.S. reporting and/or other requirements. Financial statements included in research with respect to such securities, if any, may have been prepared in accordance with non-U.S. accounting standards that may not be comparable to the financial statements of U.S. companies. Available information regarding the issuers of such securities may be limited, and such issuers may not be subject to the same auditing and reporting standards as U.S. issuers. Fluctuations in the values of national currencies, as well as the potential for governmental restrictions on currency movements, can significantly erode principal and investment returns. Market rules, conventions and practices may differ from U.S. markets, adding to transaction costs or causing delays in the purchase or sale of such securities. Securities of some non- U.S. companies may not be as liquid as securities of comparable U.S. companies.

The information contained herein may include forward-looking statements within the meaning of U.S. federal securities laws that are subject to risks and uncertainties. Factors that could cause a company's actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company's products or services, changes in foreign exchange markets, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements contained in this research are qualified in their entirety by this cautionary statement.

No finnCap party accepts any liability whatsoever for any direct or consequential loss of any kind arising out of the use or reliance on the information given. Research does not take into account the specific investment objectives and financial situation of any recipient, nor do they provide individually tailored investment advice or offer tax, regulatory, accounting or legal advice. Prior to entering into any proposed transaction, recipients should determine, in consultation with their own investment, legal, tax, regulatory and accounting advisors, the economic risks and merits, as well as the legal, tax, regulatory and accounting characteristics and consequences, of the transaction. Investors seeking to buy or sell any financial instruments discussed or recommended in research, should seek independent financial advice relating thereto.

The products discussed in research are not FDIC insured, may lose value and are not guaranteed by any finnCap party.



1 Bartholomew Close
London EC1A 7BL
Tel 020 7220 0500
Fax 020 7220 0597
Email info@finncap.com
Web WWW.finncap.com
finnCap is registered as a company in England with number 0619898.
Authorised and regulated by the Financial Conduct

Authority, Member of the London Stock Exchange